multiple sclerosis

Novartis builds case for MS drug ofatumumab as FDA decision looms
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Novartis
ofatumumab
clinical trials
MS
multiple sclerosis
Flag link:
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Sanofi posts data from contentious phase 2 multiple sclerosis trial
Fierce Biotech
Sanofi
clinical trials
MS
multiple sclerosis
Principia Biopharma
SAR442168
Flag link:
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Early treatment with Novartis' Mayzent stalls secondary progressive MS: study
Fierce Pharma
Novartis
Mayzent
MS
multiple sclerosis
Gilenya
Flag link:
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Janssen files MS pill, ahead of FDA decision on BMS’ rival
Pharmaforum
Janssen
JNJ
multiple sclerosis
MS
FDA
ponesimod
Bristol-Myers Squibb
ozanimod
Flag link:
France’s MedDay says drug for MS falls at phase 3 hurdle
France’s MedDay says drug for MS falls at phase 3 hurdle
Pharmaforum
MedDay Pharma
France
MD1003
multiple sclerosis
MS
clinical trials
Flag link:
Go or no go? Ozanimod and Fintepla await FDA verdicts
Go or no go? Ozanimod and Fintepla await FDA verdicts
EP Vantage
Bristol-Myers Squibb
ozaminod
MS
multiple sclerosis
Zogenix
Fintepla
FDA
Flag link:
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
Teva Calls on FDA to Make Copaxone a Biologic as Part of March Transition
RAPS.org
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
FDA
biologics
Flag link:
Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Novartis gets a boost in blockbuster multiple sclerosis race with Roche
Endpoints
Novartis
MS
multiple sclerosis
FDA
priority reviews
Arzerra
Flag link:
To challenge Ocrevus, German Merck takes on Aubagio
To challenge Ocrevus, German Merck takes on Aubagio
EP Vantage
Ocrevus
Merck KGaA
Aubagio
evobrutinib
MS
multiple sclerosis
Flag link:
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?
Motley Fool
Biogen
Mylan
Alzheimer's disease
patents
Tecfidera
MS
multiple sclerosis
Vumerity
Flag link:
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis
BioSpace
MS
multiple sclerosis
Biogen
Sanofi
Active Biotech
Mylan
Novartis
Adamas
Flag link:
Multiple sclerosis “win” makes the Principia shorts squirm
Multiple sclerosis “win” makes the Principia shorts squirm
EP Vantage
Principia Biopharma
SAR442168
MS
multiple sclerosis
Flag link:
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Biogen wins Tecfidera patent challenge from Mylan, sending shares way up
Fierce Pharma
Biogen
patents
Tecfidera
Mylan
multiple sclerosis
MS
Flag link:
Active Biotech is back, with one last bid for the failed MS drug Teva discarded
Active Biotech is back, with one last bid for the failed MS drug Teva discarded
Endpoints
Teva Pharmaceutical
Active Biotech
laquinimod
MS
multiple sclerosis
Flag link:
GeNeuro raises €17.5M for multiple sclerosis clinical trial
GeNeuro raises €17.5M for multiple sclerosis clinical trial
Fierce Biotech
GeNeuro
MS
multiple sclerosis
clinical trials
temelimab
Flag link:
Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
Patients Still Struggle To Balance High Costs Of MS Treatment, Despite Generic
NPR
drug pricing
generics
MS
multiple sclerosis
Flag link:
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Flag link:
Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pear Therapeutics announces first patient dosed in part II of Pear-006 feasibility study
Pharmaceutical Business Review
Pear Therapeutics
MS
multiple sclerosis
Pear-006
clinical trials
Flag link:
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Novartis
FDA
Gilenya
MS
multiple sclerosis
Mylan
Dr Reddy's
Torrent Pharmaceuticals
Aurobindo
generics
Flag link:
Treating multiple sclerosis with the help of the gut microbiome
Treating multiple sclerosis with the help of the gut microbiome
Fierce Biotech
Brigham and Women's
microbiome
microRNA
multiple sclerosis
MS
Flag link:

Pages